Navigation Links
MIT's implantable device offers continuous cancer monitoring
Date:5/14/2009

CAMBRIDGE, Mass.--Surgical removal of a tissue sample is now the standard for diagnosing cancer. Such procedures, known as biopsies, are accurate but only offer a snapshot of the tumor at a single moment in time.

Monitoring a tumor for weeks or months after the biopsy, tracking its growth and how it responds to treatment, would be much more valuable, says Michael Cima, MIT professor of materials science and engineering, who has developed the first implantable device that can do just that.

Cima and his colleagues recently reported that their device successfully tracked a tumor marker in mice for one month. The work is described in a paper published online in the journal Biosensors & Bioelectronics in April.

Such implants could one day provide up-to-the-minute information about what a tumor is doing whether it is growing or shrinking, how it's responding to treatment, and whether it has metastasized or is about to do so.

"What this does is basically take the lab and put it in the patient," said Cima, who is also an investigator at the David H. Koch Institute for Integrative Cancer Research at MIT.

The devices, which could be implanted at the time of biopsy, could also be tailored to monitor chemotherapy agents, allowing doctors to determine whether cancer drugs are reaching the tumors. They can also be designed to measure pH (acidity) or oxygen levels, which reveal tumor metabolism and how it is responding to therapy.

With current tools for detecting whether a tumor has spread, such as biopsy, by the time you have test results it's too late to prevent metastasis, said Cima.

"This is one of the tools we're going to need if we're going to turn cancer from a death sentence to a manageable disease," he said.

In the Biosensors & Bioelectronics study, human tumors were transplanted into the mice, and the researchers then used the implants to track levels of human chorionic gonadotropin, a hormone produced by human tumor cells.

The cylindrical, 5-millimeter implant contains magnetic nanoparticles coated with antibodies specific to the target molecules. Target molecules enter the implant through a semipermeable membrane, bind to the particles and cause them to clump together. That clumping can be detected by MRI (magnetic resonance imaging).

The device is made of a polymer called polyethylene, which is commonly used in orthopedic implants. The semipermeable membrane, which allows target molecules to enter but keeps the magnetic nanoparticles trapped inside, is made of polycarbonate, a compound used in many plastics.

Cima said he believes an implant to test for pH levels could be commercially available in a few years, followed by devices to test for complex chemicals such as hormones and drugs.


'/>"/>

Contact: Elizabeth Thomson
thomson@mit.edu
617-258-5402
Massachusetts Institute of Technology
Source:Eurekalert

Related medicine news :

1. Gates Foundation Commits $280 Million for Research to Fight Global TB Epidemic
2. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
3. New Study Shows Arthritis Significantly Limits Millions of Americans Ability to Work
4. Global Med Technologies(R), Inc. Submits ElDorado Donor(TM) to FDA
5. MacArthur commits $11 million to further UCSF work in maternal safety
6. Banco Popular Commits To Make A Difference Day 2007
7. Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
8. Michael J. Fox Foundation Commits Up to $2 Million for PD Drug Development Under Target Validation 2008
9. Certain Cholesterol Drugs Show Their Limits
10. Gates Foundation Commits to Expansion of HIV Prevention in China
11. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... 2017 , ... SABRE is pleased to announce the ... a graduate student from Sonora, California, who will begin her studies this fall ... in Miami, Florida, was selected from a pool of more than 50,000 applicants ...
(Date:9/22/2017)... ... September 22, 2017 , ... TopConsumerReviews.com recently awarded their ... that helps promote pancreatic health and regulate blood sugar levels . , ... can have negative side effects, and with the changes in today’s healthcare industry, ...
(Date:9/22/2017)... ... September 22, 2017 , ... “Fruit of the Spirit: “Love””: ... nature that God has created. “Fruit of the Spirit: “Love”” is the creation of ... devoted wife and mother of five. Halimah is an avid writer, her inspiration for ...
(Date:9/22/2017)... ... September 22, 2017 , ... Global Lyme Alliance (GLA), the ... and awareness, today announced the appointment of Timothy J. Sellati, Ph.D. as its ... more than 20 years of research experience with Lyme and other tick-borne diseases. ...
(Date:9/21/2017)... IL (PRWEB) , ... September 21, 2017 , ... SABRE ... to run from September 11 to the end of November. , The Chicago, Illinois, ... to their community and teach them about the ease of taking their personal safety ...
Breaking Medicine News(10 mins):
(Date:9/13/2017)... has been named the official orthopedic and sports medicine ... 2018 College Football Playoff (CFP) National Championship to be played ... Atlanta, Georgia . OrthoAtlanta is proud to be ... many activities leading up to, and including the national championship ... OrthoAtlanta serves ...
(Date:9/9/2017)... NEW YORK , Sept. 8, 2017 ... largest independent supplier of medical equipment, supplies, drugs, ... that it has entered into an agreement to acquire ... surgical equipment based in Holtsville, New York ... which specializes in supplying new and emerging medical practices, ...
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), ... partnership with Novartis Pharma AG to distribute NuvoAir,s spirometry technology ... leading mobile spirometry platform and Novartis, commitment to address the ... ... ...
Breaking Medicine Technology: